GAITHERSBURG, Md., June 22, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: NASDAQ:), a clinical-stage biopharmaceutical firm, immediately offered information on the impact of pemvidutide, its GLP-1/glucagon twin receptor agonist candidate in improvement for weight problems and metabolic dysfunction-associated steatohepatitis (MASH), on cardioinflammatory lipids on the American Diabetes Affiliation’s (ADA) 84th Scientific Periods.
Dyslipidemia is without doubt one of the most vital co-morbidities of weight problems, impacting as much as 70% of sufferers with weight problems, mentioned Vipin Okay. Garg, Ph.D., President and Chief Government Officer of Altimmune. These information add to the differentiated profile of pemvidutide and reinforce its potential to cut back inflammatory lipids related to cardiovascular plaque formation and cardiovascular threat in sufferers with weight problems.
Dysregulated lipid profiles in weight problems could cause systemic irritation and elevate heart problems (CVD) threat. To raised perceive the potential impression of pemvidutide on lipoprotein and glycoprotein biomarkers of CVD irritation, samples have been analyzed from the 12-week, randomized placebo-controlled Section 1 examine of pemvidutide in topics with chubby or weight problems however not kind 2 diabetes. Within the examine, 34 topics have been randomly assigned 1:1:1:1 to pemvidutide (1.2mg, 1.8mg and a couple of.4mg) or placebo administered once-weekly subcutaneously for 12 weeks. Lipidomic, lipoparticle and glycoprotein profiling was performed utilizing ultra-high efficiency liquid chromatography-mass spectrometry and proton nuclear magnetic resonance on plasma samples at baseline and after 12 weeks of remedy.
Serum lipids together with complete ldl cholesterol, low density lipoprotein ldl cholesterol (LDL-C), and triglycerides have been lowered by 28%, 26% and 38% respectively. The reductions in every class of those lipids weren’t correlated with weight reduction, suggesting that lipid results have been because of the direct impression of pemvidutide on lipid metabolism. An in depth evaluation confirmed pemvidutide considerably lowered small dense LDL-C, short-chain diglycerides with greater diploma of saturation, lysophosphatidylinositols, lysophosphatidylcholines and sphingolipids, all lipids with a robust affiliation with CVD. Reductions in GlycA and GlycB, biomarkers of systemic irritation which are recognized to correlate with coronary heart failure, have been additionally noticed. Along with the reductions in weight and serum lipids, remedy with pemvidutide resulted in reductions to systolic and diastolic blood stress throughout all dose teams, suggesting that pemvidutide could have pleiotropic results which will contribute to decreased CVD threat.
About Pemvidutide
Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon twin receptor agonist in improvement for the remedy of weight problems and MASH. Activation of the GLP-1 and glucagon receptors is believed to imitate the complementary results of weight loss program and train on weight reduction, with GLP-1 suppressing urge for food and glucagon rising power expenditure. Glucagon can also be acknowledged as having direct results on hepatic fats metabolism, which is believed to result in fast reductions in ranges of liver fats and serum lipids. In scientific trials to this point, once-weekly pemvidutide has demonstrated compelling weight reduction, sturdy reductions in triglycerides, LDL ldl cholesterol, liver fats content material and blood stress. The¯U.S.¯FDA has granted Quick Monitor designation to pemvidutide for the remedy of MASH. Pemvidutide just lately accomplished the MOMENTUM Section 2 weight problems trial and is being studied within the ongoing IMPACT Section 2b MASH trial.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical firm centered on growing modern next-generation peptide-based therapeutics. The Firm is growing pemvidutide, a GLP-1/glucagon twin receptor agonist for the remedy of weight problems and MASH. For extra info, please go to www.altimmune.com.
Ahead-Wanting Assertion
Any statements made on this press launch regarding future monetary or enterprise efficiency, circumstances, plans, prospects, developments, or methods and different monetary and enterprise issues, together with with out limitation, the timing of key milestones for our scientific property, and the prospects for the utility of, regulatory approval, commercializing or promoting any product or drug candidates, are forward-looking statements inside the which means of the Non-public Securities Litigation Reform Act of 1995. As well as, when or if used on this press launch, the phrases could, may, ought to, anticipate, consider, estimate, count on, intend, plan, predict and related expressions and their variants, as they relate to Altimmune, Inc. could establish forward-looking statements. The Firm cautions that these forward-looking statements are topic to quite a few assumptions, dangers, and uncertainties, which change over time. Essential components which will trigger precise outcomes to vary materially from the outcomes mentioned within the ahead wanting statements or historic expertise embrace dangers and uncertainties, together with dangers regarding: delays in regulatory evaluate, manufacturing and provide chain interruptions, entry to scientific websites, enrollment, antagonistic results on healthcare methods and disruption of the worldwide economic system; the reliability of the outcomes of research regarding human security and attainable antagonistic results ensuing from the administration of the Firm’s product candidates; the Firm’s means to fabricate scientific trial supplies on the timelines anticipated; and the success of future product developments, together with the success of future scientific trials. Additional info on the components and dangers that would have an effect on the Firm’s enterprise, monetary circumstances and outcomes of operations are contained within the Firm’s filings with the U.S. Securities and Alternate Fee, together with underneath the heading Threat Components within the Firm’s most up-to-date annual report on Kind 10-Okay and our different filings with the SEC, which can be found at www.sec.gov.
Comply with @Altimmune, Inc. on LinkedIn
Comply with @AltimmuneInc on Twitter
Firm Contact:
Richard Eisenstadt
Chief Monetary Officer
Cellphone: 240-654-1450
[email protected]
Investor Contacts:
Lee Roth
Burns McClellan
Cellphone: 646-382-3403
[email protected]
Julia Weilman
Burns McClellan
Cellphone: 646-732-4443
[email protected]
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Cellphone: 619-826-4657
[email protected]
Supply: Altimmune, Inc